# US 2019/0314479 A1 · Development of agonist epitopes of the human papillomavirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314479 A1
- Document ID: US20190314479A1
- Status: Published application
- Kind: A1
- Application number: 16/347,764
- Filed: 2017-11-06
- Published: 2019-10-17
- Earliest claimed: 2016-11-07
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services
- Inventors: Jeffrey Schlom; Kwong-Yok Tsang
- Web page: https://patentgrep.com/patent/US20190314479A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A61K 40/13: B-cells
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/46: Viral antigens
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.

## Claims

### Claim 1

A peptide comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide has no more than 20 amino acid residues.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the peptide consists of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 4 (depends on 1)

A nucleic acid encoding the peptide of claim 1.

### Claim 5 (depends on 4)

A vector comprising the nucleic acid of claim 4.

### Claim 6 (depends on 1)

A vector comprising a nucleic acid that encodes at least two peptides of claim 1.

### Claim 7 (depends on 1)

A cell comprising (i) one or more of the peptides of claim 1, (ii) one or more nucleic acids encoding (i), or (iii) one or more vectors comprising (ii).

### Claim 8 (depends on 7)

The cell of claim 7, wherein the cell is human.

### Claim 9 (depends on 7)

The cell of claim 7, wherein the cell is an antigen presenting cell or tumor cell.

### Claim 10 (depends on 1)

A composition comprising:
(a) (i) one or more of the peptides of claim 1, (ii) one or more nucleic acids encoding (i), (iii) one or more vectors comprising (ii), or (iv) one or more cells comprising (i)-(iii), and
(b) a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The composition of claim 10, further comprising an immunostimulatory/regulatory molecule.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the immunostimulatory/regulatory molecule is selected from the group consisting of interleukin (IL)-2, IL-4, IL-6, IL-12, IL-15, IL-15/IL15Ra, IL-15/IL-15Ra-Fc, interferon (IFN)-γ, tumor necrosis factor (TNF)-α, B7.1, B7.2, ICAM-1, LFA-3, CD70, RANTES, G-CSF, OX-40L, 41 BBL, anti-CTLA-4, IDO inhibitor, anti-PDL1, anti-PD1, and combinations thereof.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the immunostimulatory/molecule is selected from the group consisting of (i) a plasmid encoding IL-12 complexed with chitosan and (ii) recombinant IL-12 admixed with chitosan.

### Claim 14 (depends on 10)

The composition of claim 10, further comprising a chemotherapeutic drug, radioactive agent, antimetabolite, hormone, hormone antagonist, antibiotic, antiviral drug, antifungal drug, cyclophosphamide, or a combination thereof.

### Claim 15 (depends on 10)

The composition of claim 10, further comprising an alkylating agent, folate antagonist, purine antagonist, pyrimidine antagonist, spindle poison, topoisomerase inhibitor, apoptosis inducing agent, angiogenesis inhibitor, podophyllotoxin, nitrosourea, cisplatin, carboplatin, interferon, asparginase, tamoxifen, leuprolide, flutamide, megestrol, mitomycin, bleomycin, doxorubicin, irinotecan, taxol, geldanamycin, or a combination thereof.

### Claim 16 (depends on 10)

The composition of claim 10, further comprising Adriamycin, Alkeran, Ara-C, Busulfan, CCNU, Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol, Velban, Vincristine, VP-16, Gemcitabine, Herceptin, Irinotecan, Leustatin, Navelbine, Rittman STI-571, Taxotere, Topotecan, Capecitabine, Zevelin, Enzalutamide, calcitriol, or a combination thereof.

### Claim 17 (depends on 10)

The composition of claim 10, further comprising one or more adjuvants.

### Claim 18 (depends on 17)

The composition of claim 17, wherein one or more adjuvants is selected from the group consisting of alum, aluminum salts, aluminum phosphate, aluminum hydroxide, aluminum silica, calcium phosphate, incomplete Freund's adjuvant, QS21, MPL-A, RIBI DETOX™, and combinations thereof.

### Claim 19 (depends on 10)

The composition of claim 10, further comprising granulocyte monocyte colony stimulating factor (GM-CSF).

### Claim 20 (depends on 10)

The composition of claim 10, further comprising liposomes.

### Claim 21 (depends on 10)

A method of inhibiting HPV infection in a subject comprising administering a therapeutically effective amount of the composition of claim 10 to the subject, wherein HPV infection in the subject is inhibited.

### Claim 22 (depends on 10)

A method of enhancing an immune response against an HPV-associated cancer in a subject comprising administering a therapeutically effective amount of the composition of claim 10 to the subject, wherein the immune response in the subject is enhanced.

### Claim 23 (depends on 10)

A method of inhibiting an HPV-associated cancer in a subject comprising:
(a) obtaining lymphocytes from the subject,
(b) stimulating the lymphocytes with the composition of claim 10 to generate cytotoxic T lymphocytes ex vivo, and
(c) administering the cytotoxic T lymphocytes to the subject,
wherein the HPV-associated cancer in the subject is inhibited.

### Claim 24 (depends on 10)

A method for inhibiting a HPV-associated cancer in a subject comprising:
(a) obtaining dendritic cells from the subject,
(b) treating the dendritic cells with the composition of claim 10 ex vivo, and
(c) administering the treated dendritic cells to the subject,
wherein the HPV-associated cancer in the subject is inhibited.

### Claim 25 (depends on 10)

A method for inhibiting a HPV-associated cancer in a subject comprising:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the subject,
(b) isolating dendritic cells from the PBMCs,
(c) treating the dendritic cells with the composition of claim 10 ex vivo,
(d) activating the PBMCs with the treated dendritic cells ex vivo, and
(e) administering the activated PBMCs to the subject,
wherein the HPV-associated cancer in the subject is inhibited.

### Claim 26 (depends on 10)

A method for inhibiting a HPV-associated cancer in a subject comprising:
(a) obtaining peripheral blood mononuclear cells (PBMCs) from the subject,
(b) isolating dendritic cells from the PBMCs,
(c) treating the dendritic cells with the composition of claim 10 ex vivo,
(d) activating the PBMCs with the treated dendritic cells ex vivo,
(e) isolating T lymphocytes from the activated PBMCs ex vivo, and
(f) administering the isolated T lymphocytes to the subject,
wherein the HPV-associated cancer in the subject is inhibited.

### Claim 27

(canceled)

### Claim 28

A method of inducing an immune response against an HPV-associated cancer in a subject comprising:
(a) administering to the subject a first vector comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 and
(b) administering to the subject a second vector comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 29 (depends on 28)

The method of claim 28, wherein the nucleic acid encoding the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 is a nucleic acid encoding an HPV protein comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3.

### Claim 30 (depends on 29)

The method of claim 29, wherein the HPV protein is an HPV E6 protein.

### Claim 31 (depends on 30)

The method of claim 30, wherein the HPV E6 protein is an HPV-16 E6 protein.

### Claim 32 (depends on 29)

The method of claim 29, wherein the HPV protein is an HPV E7 protein.

### Claim 33 (depends on 32)

The method of claim 32, wherein the HPV E6 protein is an HPV-16 E7 protein.
